BioN­Tech to ex­plore po­ten­tial of de­liv­er­ing mR­NA vac­cines oral­ly with new part­ner

Af­ter a Covid-19 vac­cine suc­cess with part­ner Pfiz­er, and as the rest of its mR­NA pipeline starts churn­ing out da­ta, BioN­Tech wants to go an­oth­er de­liv­ery route with its jabs: oral­ly.

The Ger­man biotech is pay­ing an undis­closed amount to gain ex­clu­sive ac­cess to New Jer­sey-based Mati­nas Bio­Phar­ma’s lipid nanocrys­tal, or LNC, drug de­liv­ery plat­form. Keep in mind, that BioN­Tech/Pfiz­er’s Comir­naty is de­liv­ered with lipid nanopar­ti­cles.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER